What clinical trials or EU notified body approvals supported Neurocept regulatory filings by 2025?

1. No public clinical‑trial record for “Neurocept” found in current reporting

Searchable coverage and summaries in the documents you provided — including product pages and 2025 neuro/neurology review sources — describe Neurocept as a brain‑health supplement and reference “some clinical trials” for adaptogenic ingredients, but none of the items cite registered clinical trials, ClinicalTrials.gov identifiers, peer‑reviewed trial publications, or sponsor filings for a therapeutic product called Neurocept ^{[1] [2] [5]}. Available sources do not mention registered Phase 1–3 trials or pivotal studies for a Neurocept drug.

2. Company and promotional sources frame Neurocept as a supplement, not a regulated therapeutic

The Neurocept official site and linked review pieces position the product as a cognitive support/nootropic formula that relies on “adaptogenic herb shown in some clinical trials to reduce fatigue, enhance focus, and support mental clarity” — language common to dietary supplement marketing rather than drug approval dossiers ^{[1] [2]}. Those sources emphasize consumer benefits and expert reviews but do not claim CE marking, CE‑type device approvals, or EMA marketing authorisation, and they do not provide the kind of clinical data typically cited in regulatory filings ^{[1] [2]}.

3. EU notified‑body approvals are a distinct, traceable process not reflected in the sources

Notified‑body decisions (for devices) and EMA/CHMP marketing‑authorisation actions (for medicines) are documented in EMA meeting reports and Lancet overviews; the 2025 EMA reporting enumerates dozens of medicines and biosimilars recommended by CHMP across multiple months but contains no entry naming Neurocept as a product receiving EU marketing authorisation or a notified‑body certificate ^{[4] [3]}. In short, the authoritative EU/EMA coverage cited does not associate Neurocept with any regulatory milestone in 2025 ^{[4] [3]}.

4. What the sources do document about neuro‑therapy regulation in 2025 (context)

2025 reporting shows an active EMA calendar with CHMP recommendations across the year and broader discussion of EU pharmaceutical legislation changes; independent summaries list many approvals and biosimilars but do not include Neurocept ^{[4] [3] [6]}. Separately, neuro‑therapeutics literature and pipeline reviews catalogue hundreds of registered clinical trials for Alzheimer disease and other CNS targets — illustrating the density of trials needed to support regulatory filings for bona fide therapeutics — but these academic and regulatory summaries do not mention Neurocept ^{[7] [8]}.

5. Alternative explanations and reporting limitations

There are three possible reasons for the gap in the available sources: Neurocept may be a consumer supplement whose supporting “clinical trials” are small, unpublished, or proprietary and therefore absent from public registries; it may be marketed under a different legal/trade name in regulatory filings; or the product simply has not pursued EU notified‑body certification or EMA approval and instead relies on consumer product channels ^{[1] [2]}. The documents you provided do not confirm which of these is true — available sources do not mention trial registrations, notified‑body certificates, or EMA filings tied to Neurocept.

6. How to verify further (practical next steps)

To resolve the question definitively, consult ClinicalTrials.gov and the EU’s Eudamed/Notified Body databases for any entries under the company name or product trade name; request full study reports or trial IDs from the manufacturer; and check EMA/CHMP meeting minutes and national competent‑authority registers for marketing‑authorisation applications. The current corpus you supplied contains neither those records nor independent regulatory confirmations ^{[8] [3] [1]}.

Limitations: reporting cited here is limited to the documents you provided; no other web searches or registries were consulted. All factual points above are supported by the cited sources ^{[1] [2] [4] [3] [7] [8]}.